Botulinum Toxin Type A

Identification

Name
Botulinum Toxin Type A
Accession Number
DB00083  (BTD00092, BIOD00092)
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Purified botulinum toxin from Clostridium botulinum, purified from culture via dialysis and acid precipitation.

Protein structure
Db00083
Protein chemical formula
C6760H10447N1743O2010S32
Protein average weight
149322.7 Da
Sequences
>Botulinum Toxin Type A Sequence
MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLN
PPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGG
STIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGY
GSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPN
RVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKA
KSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKV
LNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFT
GLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEE
ITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNG
KKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEA
AMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSG
AVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAK
VNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKA
MININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDK
VNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINI
GSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNN
EYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTIT
NNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELN
EKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPR
GSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQA
GVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAK
LVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL
Download FASTA Format
Synonyms
  • AbobotulinumtoxinA
  • BoNT/A
  • Bontoxilysin A
  • Botulinum neurotoxin type A precursor
  • BTX-A
  • IncobotulinumtoxinA
  • OnabotulinumtoxinA
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BotoxPowder, for solution100 unitIntramuscularAllergan1992-12-31Not applicableCanada
BotoxInjection, powder, lyophilized, for solution200 [USP'U]/1Intradermal; IntramuscularAllergan2010-01-11Not applicableUs
BotoxInjection, powder, lyophilized, for solution100 [USP'U]/1Intradermal; IntramuscularAllergan1989-12-15Not applicableUs
BOTOX CosmeticInjection, powder, lyophilized, for solution100 [USP'U]/1IntramuscularAllergan2008-05-20Not applicableUs
BOTOX CosmeticInjection, powder, lyophilized, for solution50 [USP'U]/1IntramuscularAllergan2008-07-15Not applicableUs
BOTOX CosmeticPowder, for solution100 unitIntramuscularAllergan2001-05-07Not applicableCanada
DysportInjection, powder, lyophilized, for solution300 U/1IntramuscularIpsen Biopharmaceuticals, Inc.2009-11-02Not applicableUs
DysportInjection, powder, lyophilized, for solution300 [USP'U]/1IntramuscularMedicis Pharmaceutical Corporation2009-05-252015-03-31Us
DysportInjection, powder, lyophilized, for solution500 U/1IntramuscularIpsen Biopharmaceuticals, Inc.2009-11-02Not applicableUs
DysportInjection, powder, lyophilized, for solution300 U/1IntramuscularGalderma2009-11-02Not applicableUs
Categories
UNII
E211KPY694
CAS number
93384-43-1

Pharmacology

Indication

For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. Also used cosmetically to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating.

Associated Conditions
Associated Therapies
Pharmacodynamics

A 150 kDa neurotoxic protein produced from fermentation of Hall strain Clostridium botulinum type A grown in a medium containing casein hydrolysate, glucose and yeast extract. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin, and several accessory proteins. Botulinum Toxin Type A is not expected to be present in the peripheral blood at measurable levels following IM or intradermal injection at the recommended doses. The recommended quantities of neurotoxin administered at each treatment session are not expected to result in systemic, overt distant clinical effects, i.e. muscle weakness, in patients without other neuromuscular dysfunction. However, sub-clinical systemic effects have been shown by single-fiber electromyography after IM doses of botulinum toxins appropriate to produce clinically observable local muscle weakness.

Mechanism of action

Botulinum Toxin Type A blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings.

TargetActionsOrganism
ASynaptosomal-associated protein 25
inhibitor
Human
URho-related GTP-binding protein RhoBNot AvailableHuman
Absorption

The chemical complexity of Botulinum Toxin Type A combined with its extreme potency limits the opportunity to study its pharmacokinetic profile in humans. Therefore, no human pharmacokinetic studies have been performed. Botulinum Toxin Type A is injected directly into the target organ, a skeletal muscle. Thus, bioavailability of the intravenous or oral route is not of clinical relevance.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Based on toxicological studies, it has been estimated that the human LD50 by injection is approximately 2800 Units, equivalent to 28 individual vials of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex (100 Units) for a 70 kg adult. When injected intramuscularly, Botulinum Toxin Type A has been shown to be teratogenic or to have embryocidal effects in some animal species.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(2-benzhydryloxyethyl)diethyl-methylammonium iodideThe risk or severity of adverse effects can be increased when (2-benzhydryloxyethyl)diethyl-methylammonium iodide is combined with Botulinum Toxin Type A.Experimental
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Botulinum Toxin Type A.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Botulinum Toxin Type A.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Botulinum Toxin Type A.Experimental, Illicit
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe risk or severity of adverse effects can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Botulinum Toxin Type A.Experimental
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Botulinum Toxin Type A.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Botulinum Toxin Type A.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Botulinum Toxin Type A.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Botulinum Toxin Type A.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Botulinum Toxin Type A.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Botulinum Toxin Type A.Approved
Acetyl sulfisoxazoleThe risk or severity of adverse effects can be increased when Acetyl sulfisoxazole is combined with Botulinum Toxin Type A.Approved, Vet Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Acetylglycinamide chloral hydrate is combined with Botulinum Toxin Type A.Experimental
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Botulinum Toxin Type A.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Adinazolam is combined with Botulinum Toxin Type A.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Botulinum Toxin Type A.Investigational
AgmatineThe risk or severity of adverse effects can be increased when Agmatine is combined with Botulinum Toxin Type A.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Botulinum Toxin Type A.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Botulinum Toxin Type A.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Botulinum Toxin Type A.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Botulinum Toxin Type A.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Allobarbital is combined with Botulinum Toxin Type A.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Botulinum Toxin Type A.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Almotriptan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Botulinum Toxin Type A.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Botulinum Toxin Type A.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Botulinum Toxin Type A.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Alverine.Approved, Investigational
AmantadineThe risk or severity of adverse effects can be increased when Amantadine is combined with Botulinum Toxin Type A.Approved
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Botulinum Toxin Type A.Illicit, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Botulinum Toxin Type A.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Botulinum Toxin Type A.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Botulinum Toxin Type A.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Botulinum Toxin Type A.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Botulinum Toxin Type A.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Botulinum Toxin Type A.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Botulinum Toxin Type A.Approved, Illicit, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Aniracetam is combined with Botulinum Toxin Type A.Experimental
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Botulinum Toxin Type A.Approved
APD791The risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Apramycin is combined with Botulinum Toxin Type A.Experimental, Vet Approved
AprobarbitalThe risk or severity of adverse effects can be increased when Aprobarbital is combined with Botulinum Toxin Type A.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Apronalide is combined with Botulinum Toxin Type A.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Arbekacin is combined with Botulinum Toxin Type A.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Botulinum Toxin Type A.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Aripiprazole lauroxil.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Botulinum Toxin Type A.Approved
AtomoxetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Botulinum Toxin Type A.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Botulinum Toxin Type A.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Botulinum Toxin Type A.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Botulinum Toxin Type A.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Botulinum Toxin Type A.Investigational, Vet Approved
AZD-3043The risk or severity of adverse effects can be increased when AZD-3043 is combined with Botulinum Toxin Type A.Investigational
AzelastineBotulinum Toxin Type A may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Azosemide is combined with Botulinum Toxin Type A.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Botulinum Toxin Type A.Approved
BarbexacloneThe risk or severity of adverse effects can be increased when Barbexaclone is combined with Botulinum Toxin Type A.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Botulinum Toxin Type A.Illicit
Barbituric acid derivativeThe risk or severity of adverse effects can be increased when Barbituric acid derivative is combined with Botulinum Toxin Type A.Experimental, Illicit
BeclamideThe risk or severity of adverse effects can be increased when Beclamide is combined with Botulinum Toxin Type A.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Bekanamycin is combined with Botulinum Toxin Type A.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Botulinum Toxin Type A.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Botulinum Toxin Type A.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Botulinum Toxin Type A.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Botulinum Toxin Type A.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Botulinum Toxin Type A.Approved
BenziloneThe risk or severity of adverse effects can be increased when Benzilone is combined with Botulinum Toxin Type A.Experimental
BenzoctamineThe risk or severity of adverse effects can be increased when Benzoctamine is combined with Botulinum Toxin Type A.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Botulinum Toxin Type A.Approved, Illicit
BenzquinamideThe risk or severity of adverse effects can be increased when Benzquinamide is combined with Botulinum Toxin Type A.Withdrawn
BenzthiazideThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Botulinum Toxin Type A.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Botulinum Toxin Type A.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Botulinum Toxin Type A.Experimental
BifemelaneThe risk or severity of adverse effects can be increased when Bifemelane is combined with Botulinum Toxin Type A.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Botulinum Toxin Type A.Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Botulinum Toxin Type A.Approved, Investigational
BL-1020The risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Blonanserin.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Botulinum Toxin Type A.Experimental
Botulinum Toxin Type BBotulinum Toxin Type A may increase the adverse neuromuscular activities of Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Botulinum Toxin Type A.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type A.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Brivaracetam is combined with Botulinum Toxin Type A.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Botulinum Toxin Type A.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Botulinum Toxin Type A.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Botulinum Toxin Type A.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Botulinum Toxin Type A.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Botulinum Toxin Type A.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Botulinum Toxin Type A.Approved, Investigational, Withdrawn
BuclizineThe risk or severity of adverse effects can be increased when Buclizine is combined with Botulinum Toxin Type A.Approved
BufotenineThe risk or severity of adverse effects can be increased when Bufotenine is combined with Botulinum Toxin Type A.Experimental, Illicit
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Botulinum Toxin Type A.Approved
BuprenorphineBotulinum Toxin Type A may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Botulinum Toxin Type A.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Botulinum Toxin Type A.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Botulinum Toxin Type A.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Botulinum Toxin Type A.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Butaperazine is combined with Botulinum Toxin Type A.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Botulinum Toxin Type A.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Botulinum Toxin Type A.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Botulinum Toxin Type A.Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Butylscopolamine is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Cabergoline.Approved
CamazepamThe risk or severity of adverse effects can be increased when Camazepam is combined with Botulinum Toxin Type A.Approved, Illicit
CamylofinThe risk or severity of adverse effects can be increased when Camylofin is combined with Botulinum Toxin Type A.Experimental
CannabidiolThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Capreomycin is combined with Botulinum Toxin Type A.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Captodiame is combined with Botulinum Toxin Type A.Approved, Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Botulinum Toxin Type A.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Botulinum Toxin Type A.Approved
CarbromalThe risk or severity of adverse effects can be increased when Carbromal is combined with Botulinum Toxin Type A.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Botulinum Toxin Type A.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Botulinum Toxin Type A.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Carisbamate is combined with Botulinum Toxin Type A.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Botulinum Toxin Type A.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Botulinum Toxin Type A.Withdrawn
CathinoneThe risk or severity of adverse effects can be increased when Cathinone is combined with Botulinum Toxin Type A.Illicit
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Botulinum Toxin Type A.Approved, Investigational
CerlapirdineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Botulinum Toxin Type A.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Botulinum Toxin Type A.Approved, Illicit, Investigational, Vet Approved
Chloramine-TThe risk or severity of adverse effects can be increased when Chloramine-T is combined with Botulinum Toxin Type A.Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Botulinum Toxin Type A.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Botulinum Toxin Type A.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Botulinum Toxin Type A.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Botulinum Toxin Type A.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Botulinum Toxin Type A.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Chlorphenesin.Approved, Experimental
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Botulinum Toxin Type A.Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Botulinum Toxin Type A.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Botulinum Toxin Type A.Approved, Investigational, Withdrawn
ChlorsulfaquinoxalineThe risk or severity of adverse effects can be increased when Chlorsulfaquinoxaline is combined with Botulinum Toxin Type A.Investigational
ChlortetracyclineThe risk or severity of adverse effects can be increased when Chlortetracycline is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Botulinum Toxin Type A.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Botulinum Toxin Type A.Approved
CilansetronThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Cilansetron.Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Cinolazepam is combined with Botulinum Toxin Type A.Approved
CisaprideThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Cisatracurium is combined with Botulinum Toxin Type A.Approved
CitalopramThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Botulinum Toxin Type A.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Botulinum Toxin Type A.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Botulinum Toxin Type A.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Botulinum Toxin Type A.Approved, Illicit
ClofenamideThe risk or severity of adverse effects can be increased when Clofenamide is combined with Botulinum Toxin Type A.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Botulinum Toxin Type A.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Clomocycline is combined with Botulinum Toxin Type A.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Botulinum Toxin Type A.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Botulinum Toxin Type A.Approved
ClopamideThe risk or severity of adverse effects can be increased when Clopamide is combined with Botulinum Toxin Type A.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Botulinum Toxin Type A.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Botulinum Toxin Type A.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Clorexolone is combined with Botulinum Toxin Type A.Experimental
ClorsulonThe risk or severity of adverse effects can be increased when Clorsulon is combined with Botulinum Toxin Type A.Vet Approved
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Botulinum Toxin Type A.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Clotiazepam is combined with Botulinum Toxin Type A.Approved, Illicit
CloxazolamThe risk or severity of adverse effects can be increased when Cloxazolam is combined with Botulinum Toxin Type A.Approved, Investigational
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Botulinum Toxin Type A.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Botulinum Toxin Type A.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Botulinum Toxin Type A.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Colistimethate is combined with Botulinum Toxin Type A.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Colistin is combined with Botulinum Toxin Type A.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Botulinum Toxin Type A.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Botulinum Toxin Type A.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Cyclobarbital is combined with Botulinum Toxin Type A.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Botulinum Toxin Type A.Approved
CyclopentamineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Cyclopentamine.Withdrawn
CyclopenthiazideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Botulinum Toxin Type A.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Botulinum Toxin Type A.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Botulinum Toxin Type A.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Cyclothiazide is combined with Botulinum Toxin Type A.Approved
CycrimineThe risk or severity of adverse effects can be increased when Cycrimine is combined with Botulinum Toxin Type A.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Botulinum Toxin Type A.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Botulinum Toxin Type A.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Botulinum Toxin Type A.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Botulinum Toxin Type A.Approved, Investigational
DarunavirThe risk or severity of adverse effects can be increased when Darunavir is combined with Botulinum Toxin Type A.Approved
DeanolThe risk or severity of adverse effects can be increased when Deanol is combined with Botulinum Toxin Type A.Experimental
DecamethoniumThe therapeutic efficacy of Decamethonium can be increased when used in combination with Botulinum Toxin Type A.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Delorazepam is combined with Botulinum Toxin Type A.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Demeclocycline is combined with Botulinum Toxin Type A.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Botulinum Toxin Type A.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Botulinum Toxin Type A.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Botulinum Toxin Type A.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Botulinum Toxin Type A.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Botulinum Toxin Type A.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Botulinum Toxin Type A.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Botulinum Toxin Type A.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Botulinum Toxin Type A.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Dextofisopam is combined with Botulinum Toxin Type A.Investigational
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Botulinum Toxin Type A.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Botulinum Toxin Type A.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Botulinum Toxin Type A.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Botulinum Toxin Type A.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Botulinum Toxin Type A.Approved, Illicit, Investigational, Vet Approved
DiazoxideThe risk or severity of adverse effects can be increased when Diazoxide is combined with Botulinum Toxin Type A.Approved
DibekacinThe risk or severity of adverse effects can be increased when Dibekacin is combined with Botulinum Toxin Type A.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Botulinum Toxin Type A.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Botulinum Toxin Type A.Approved, Illicit
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Botulinum Toxin Type A.Approved, Investigational
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Botulinum Toxin Type A.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Botulinum Toxin Type A.Experimental
DifemerineThe risk or severity of adverse effects can be increased when Difemerine is combined with Botulinum Toxin Type A.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Botulinum Toxin Type A.Approved, Illicit
DihexyverineThe risk or severity of adverse effects can be increased when Dihexyverine is combined with Botulinum Toxin Type A.Experimental
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Botulinum Toxin Type A.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Botulinum Toxin Type A.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Botulinum Toxin Type A.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Botulinum Toxin Type A.Investigational, Vet Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Botulinum Toxin Type A.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Botulinum Toxin Type A.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Botulinum Toxin Type A.Experimental, Illicit
DimetindeneThe risk or severity of adverse effects can be increased when Dimetindene is combined with Botulinum Toxin Type A.Approved, Investigational
DiphemanilThe risk or severity of adverse effects can be increased when Diphemanil is combined with Botulinum Toxin Type A.Experimental
Diphemanil MethylsulfateThe risk or severity of adverse effects can be increased when Diphemanil Methylsulfate is combined with Botulinum Toxin Type A.Approved, Vet Approved, Withdrawn
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Botulinum Toxin Type A.Approved, Investigational
DiphenidolThe risk or severity of adverse effects can be increased when Diphenidol is combined with Botulinum Toxin Type A.Approved, Investigational, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Botulinum Toxin Type A.Approved, Illicit
DisopyramideThe risk or severity of adverse effects can be increased when Disopyramide is combined with Botulinum Toxin Type A.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Botulinum Toxin Type A.Experimental
DolasetronThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Domoic Acid.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Botulinum Toxin Type A.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Botulinum Toxin Type A.Approved
DotarizineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Dotarizine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Doxacurium is combined with Botulinum Toxin Type A.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Doxefazepam is combined with Botulinum Toxin Type A.Experimental
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Botulinum Toxin Type A.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type A.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Botulinum Toxin Type A.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type A.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type A.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Botulinum Toxin Type A.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Botulinum Toxin Type A.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Botulinum Toxin Type A.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Edivoxetine is combined with Botulinum Toxin Type A.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Botulinum Toxin Type A.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Eletriptan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Botulinum Toxin Type A.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Eltoprazine.Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Botulinum Toxin Type A.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Emylcamate is combined with Botulinum Toxin Type A.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Botulinum Toxin Type A.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Botulinum Toxin Type A.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Epinastine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Botulinum Toxin Type A.Approved, Investigational
EslicarbazepineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Eslicarbazepine.Approved
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Botulinum Toxin Type A.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Botulinum Toxin Type A.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Botulinum Toxin Type A.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Eszopiclone.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Botulinum Toxin Type A.Approved, Investigational
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Botulinum Toxin Type A.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Ethadione is combined with Botulinum Toxin Type A.Experimental
EthanolBotulinum Toxin Type A may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Botulinum Toxin Type A.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Botulinum Toxin Type A.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Botulinum Toxin Type A.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Botulinum Toxin Type A.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Botulinum Toxin Type A.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Botulinum Toxin Type A.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Botulinum Toxin Type A.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Botulinum Toxin Type A.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Botulinum Toxin Type A.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Botulinum Toxin Type A.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Etiracetam is combined with Botulinum Toxin Type A.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Botulinum Toxin Type A.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Botulinum Toxin Type A.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Botulinum Toxin Type A.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Botulinum Toxin Type A.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Botulinum Toxin Type A.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Fabomotizole is combined with Botulinum Toxin Type A.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Botulinum Toxin Type A.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Botulinum Toxin Type A.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenpiveriniumThe risk or severity of adverse effects can be increased when Fenpiverinium is combined with Botulinum Toxin Type A.Experimental
FenquizoneThe risk or severity of adverse effects can be increased when Fenquizone is combined with Botulinum Toxin Type A.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Botulinum Toxin Type A.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Fenyramidol.Experimental
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Botulinum Toxin Type A.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Botulinum Toxin Type A.Approved, Investigational
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Botulinum Toxin Type A.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Botulinum Toxin Type A.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Botulinum Toxin Type A.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Botulinum Toxin Type A.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Botulinum Toxin Type A.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Botulinum Toxin Type A.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Botulinum Toxin Type A.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Botulinum Toxin Type A.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Botulinum Toxin Type A.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Botulinum Toxin Type A.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Botulinum Toxin Type A.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Botulinum Toxin Type A.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Botulinum Toxin Type A.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Botulinum Toxin Type A.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Framycetin is combined with Botulinum Toxin Type A.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Botulinum Toxin Type A.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Botulinum Toxin Type A.Approved, Investigational
Gabapentin enacarbilThe risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Botulinum Toxin Type A.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Gaboxadol is combined with Botulinum Toxin Type A.Investigational
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Botulinum Toxin Type A.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Botulinum Toxin Type A.Approved
Gamma hydroxybutyric acidThe risk or severity of adverse effects can be increased when Gamma hydroxybutyric acid is combined with Botulinum Toxin Type A.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Gantacurium Chloride is combined with Botulinum Toxin Type A.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Gedocarnil is combined with Botulinum Toxin Type A.Experimental
GeneticinThe risk or severity of adverse effects can be increased when Geneticin is combined with Botulinum Toxin Type A.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Gentamicin is combined with Botulinum Toxin Type A.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when GENTAMICIN C1A is combined with Botulinum Toxin Type A.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Botulinum Toxin Type A.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Botulinum Toxin Type A.Approved, Illicit
GlycodiazineThe risk or severity of adverse effects can be increased when Glycodiazine is combined with Botulinum Toxin Type A.Approved, Investigational
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
GranisetronThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Botulinum Toxin Type A.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Botulinum Toxin Type A.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Botulinum Toxin Type A.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Botulinum Toxin Type A.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Botulinum Toxin Type A.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Heptabarbital is combined with Botulinum Toxin Type A.Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Botulinum Toxin Type A.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Hexafluronium.Approved
HexapropymateThe risk or severity of adverse effects can be increased when Hexapropymate is combined with Botulinum Toxin Type A.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Botulinum Toxin Type A.Approved
HexocycliumThe risk or severity of adverse effects can be increased when Hexocyclium is combined with Botulinum Toxin Type A.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Botulinum Toxin Type A.Approved
Homatropine MethylbromideThe risk or severity of adverse effects can be increased when Homatropine Methylbromide is combined with Botulinum Toxin Type A.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Botulinum Toxin Type A.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Botulinum Toxin Type A.Approved, Vet Approved
HydrocodoneBotulinum Toxin Type A may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Botulinum Toxin Type A.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Botulinum Toxin Type A.Approved, Illicit
HydroxyfasudilThe risk or severity of adverse effects can be increased when Hydroxyfasudil is combined with Botulinum Toxin Type A.Experimental
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type A.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Hygromycin B is combined with Botulinum Toxin Type A.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Botulinum Toxin Type A.Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Botulinum Toxin Type A.Investigational
IdalopirdineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Idalopirdine.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Botulinum Toxin Type A.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Botulinum Toxin Type A.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Imagabalin is combined with Botulinum Toxin Type A.Investigational
ImidafenacinThe risk or severity of adverse effects can be increased when Imidafenacin is combined with Botulinum Toxin Type A.Approved, Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum Toxin Type A.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Imipramine oxide is combined with Botulinum Toxin Type A.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Botulinum Toxin Type A.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Botulinum Toxin Type A.Investigational
IpratropiumThe risk or severity of adverse effects can be increased when Ipratropium is combined with Botulinum Toxin Type A.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Botulinum Toxin Type A.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Botulinum Toxin Type A.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Botulinum Toxin Type A.Withdrawn
IsepamicinThe risk or severity of adverse effects can be increased when Isepamicin is combined with Botulinum Toxin Type A.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Botulinum Toxin Type A.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Botulinum Toxin Type A.Approved, Vet Approved
IsopropamideThe risk or severity of adverse effects can be increased when Isopropamide is combined with Botulinum Toxin Type A.Approved, Vet Approved
KanamycinThe risk or severity of adverse effects can be increased when Kanamycin is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Botulinum Toxin Type A.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Botulinum Toxin Type A.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Botulinum Toxin Type A.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Botulinum Toxin Type A.Approved, Nutraceutical, Withdrawn
LacosamideThe risk or severity of adverse effects can be increased when Lacosamide is combined with Botulinum Toxin Type A.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Botulinum Toxin Type A.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Lanicemine is combined with Botulinum Toxin Type A.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Lasmiditan.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Botulinum Toxin Type A.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Botulinum Toxin Type A.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Botulinum Toxin Type A.Approved
Levomethadyl acetateThe risk or severity of adverse effects can be increased when Levomethadyl acetate is combined with Botulinum Toxin Type A.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Botulinum Toxin Type A.Approved
LincomycinThe risk or severity of adverse effects can be increased when Lincomycin is combined with Botulinum Toxin Type A.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Linezolid.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Lithium cation is combined with Botulinum Toxin Type A.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Botulinum Toxin Type A.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Botulinum Toxin Type A.Experimental
LofexidineThe therapeutic efficacy of Botulinum Toxin Type A can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Botulinum Toxin Type A.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Botulinum Toxin Type A.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Botulinum Toxin Type A.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Botulinum Toxin Type A.Approved
LorpiprazoleThe therapeutic efficacy of Botulinum Toxin Type A can be increased when used in combination with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Lortalamine.Experimental
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Botulinum Toxin Type A.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Lumateperone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Botulinum Toxin Type A.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Lymecycline is combined with Botulinum Toxin Type A.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Botulinum Toxin Type A.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with m-Chlorophenylpiperazine.Investigational
MafenideThe risk or severity of adverse effects can be increased when Mafenide is combined with Botulinum Toxin Type A.Approved, Vet Approved
Magnesium acetateThe risk or severity of adverse effects can be increased when Magnesium acetate is combined with Botulinum Toxin Type A.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Magnesium acetate tetrahydrate is combined with Botulinum Toxin Type A.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Botulinum Toxin Type A.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Magnesium aspartate is combined with Botulinum Toxin Type A.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Botulinum Toxin Type A.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Magnesium cation is combined with Botulinum Toxin Type A.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Magnesium chloride is combined with Botulinum Toxin Type A.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Magnesium citrate is combined with Botulinum Toxin Type A.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Magnesium gluconate is combined with Botulinum Toxin Type A.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Magnesium glycinate is combined with Botulinum Toxin Type A.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Botulinum Toxin Type A.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Magnesium orotate is combined with Botulinum Toxin Type A.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Magnesium oxide is combined with Botulinum Toxin Type A.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Botulinum Toxin Type A.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Magnesium silicate is combined with Botulinum Toxin Type A.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Magnesium stearate is combined with Botulinum Toxin Type A.Investigational
Magnesium sulfateThe therapeutic efficacy of Botulinum Toxin Type A can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Botulinum Toxin Type A.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum Toxin Type A.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Botulinum Toxin Type A.Experimental
MazindolThe risk or severity of adverse effects can be increased when Mazindol is combined with Botulinum Toxin Type A.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Botulinum Toxin Type A.Withdrawn
MebeverineThe risk or severity of adverse effects can be increased when Mebeverine is combined with Botulinum Toxin Type A.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Botulinum Toxin Type A.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Mebutamate is combined with Botulinum Toxin Type A.Approved
MebutizideThe risk or severity of adverse effects can be increased when Mebutizide is combined with Botulinum Toxin Type A.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Botulinum Toxin Type A.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Botulinum Toxin Type A.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Botulinum Toxin Type A.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Medifoxamine is combined with Botulinum Toxin Type A.Experimental
MefrusideThe risk or severity of adverse effects can be increased when Mefruside is combined with Botulinum Toxin Type A.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Botulinum Toxin Type A.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Botulinum Toxin Type A.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Botulinum Toxin Type A.Approved, Investigational
MepenzolateThe risk or severity of adverse effects can be increased when Mepenzolate is combined with Botulinum Toxin Type A.Approved
MephenesinThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Mephenoxalone is combined with Botulinum Toxin Type A.Experimental
MephenytoinThe risk or severity of adverse effects can be increased when Mephenytoin is combined with Botulinum Toxin Type A.Approved, Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Botulinum Toxin Type A.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Botulinum Toxin Type A.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Botulinum Toxin Type A.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Botulinum Toxin Type A.Approved
MetergolineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Methacycline is combined with Botulinum Toxin Type A.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Botulinum Toxin Type A.Approved
Methadyl acetateThe risk or severity of adverse effects can be increased when Methadyl acetate is combined with Botulinum Toxin Type A.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Botulinum Toxin Type A.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Botulinum Toxin Type A.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Botulinum Toxin Type A.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Botulinum Toxin Type A.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Metharbital is combined with Botulinum Toxin Type A.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Botulinum Toxin Type A.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Botulinum Toxin Type A.Approved
MethotrimeprazineBotulinum Toxin Type A may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
MethscopolamineThe risk or severity of adverse effects can be increased when Methscopolamine is combined with Botulinum Toxin Type A.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Botulinum Toxin Type A.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Botulinum Toxin Type A.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Botulinum Toxin Type A.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Methylpentynol is combined with Botulinum Toxin Type A.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Botulinum Toxin Type A.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Botulinum Toxin Type A.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Methyprylon is combined with Botulinum Toxin Type A.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Methysergide.Approved
MeticraneThe risk or severity of adverse effects can be increased when Meticrane is combined with Botulinum Toxin Type A.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Botulinum Toxin Type A.Approved
MetocurineThe risk or severity of adverse effects can be increased when Metocurine is combined with Botulinum Toxin Type A.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Metocurine Iodide is combined with Botulinum Toxin Type A.Approved, Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Botulinum Toxin Type A.Approved
MetyrosineBotulinum Toxin Type A may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Mianserin is combined with Botulinum Toxin Type A.Approved, Investigational
MicronomicinThe risk or severity of adverse effects can be increased when Micronomicin is combined with Botulinum Toxin Type A.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Botulinum Toxin Type A.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Botulinum Toxin Type A.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Botulinum Toxin Type A.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type A.Approved, Investigational
MirtazapineBotulinum Toxin Type A may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumThe risk or severity of adverse effects can be increased when Mivacurium is combined with Botulinum Toxin Type A.Approved
MK-212The risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with MK-212.Investigational
MMDAThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Botulinum Toxin Type A.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Botulinum Toxin Type A.Approved
MoperoneThe risk or severity of adverse effects can be increased when Moperone is combined with Botulinum Toxin Type A.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Botulinum Toxin Type A.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Mosapramine is combined with Botulinum Toxin Type A.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when MRK-409 is combined with Botulinum Toxin Type A.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type A.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Botulinum Toxin Type A.Approved
NaluzotanThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Neamine is combined with Botulinum Toxin Type A.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Botulinum Toxin Type A.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when Neocitrullamon is combined with Botulinum Toxin Type A.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Neomycin is combined with Botulinum Toxin Type A.Approved, Vet Approved
NeosaxitoxinThe therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Botulinum Toxin Type A.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Netilmicin is combined with Botulinum Toxin Type A.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Botulinum Toxin Type A.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Niaprazine is combined with Botulinum Toxin Type A.Experimental
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Botulinum Toxin Type A.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Nicotine.Approved
NisoxetineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Botulinum Toxin Type A.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Botulinum Toxin Type A.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Nomifensine is combined with Botulinum Toxin Type A.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with Botulinum Toxin Type A.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Botulinum Toxin Type A.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Botulinum Toxin Type A.Approved
OcinaplonThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Ocinaplon.Investigational
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Botulinum Toxin Type A.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Botulinum Toxin Type A.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Botulinum Toxin Type A.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Botulinum Toxin Type A.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Botulinum Toxin Type A.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Botulinum Toxin Type A.Approved, Illicit
OrphenadrineBotulinum Toxin Type A may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Orvepitant is combined with Botulinum Toxin Type A.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Botulinum Toxin Type A.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Botulinum Toxin Type A.Experimental, Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Oxaflozane is combined with Botulinum Toxin Type A.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Botulinum Toxin Type A.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Botulinum Toxin Type A.Approved
Oxazepam acetateThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Oxazepam acetate.Experimental
OxcarbazepineThe risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Botulinum Toxin Type A.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Oxiracetam is combined with Botulinum Toxin Type A.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Oxitriptan is combined with Botulinum Toxin Type A.Approved, Investigational, Nutraceutical
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Botulinum Toxin Type A.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Botulinum Toxin Type A.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Botulinum Toxin Type A.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Botulinum Toxin Type A.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Oxypertine is combined with Botulinum Toxin Type A.Experimental
OxyphencyclimineThe risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Botulinum Toxin Type A.Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Botulinum Toxin Type A.Approved
OxytetracyclineThe risk or severity of adverse effects can be increased when Oxytetracycline is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
PagocloneThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Pagoclone.Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Botulinum Toxin Type A.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Palonosetron.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Botulinum Toxin Type A.Approved
ParaldehydeBotulinum Toxin Type A may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Paramethadione is combined with Botulinum Toxin Type A.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Botulinum Toxin Type A.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Botulinum Toxin Type A.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Botulinum Toxin Type A.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Botulinum Toxin Type A.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Penimepicycline is combined with Botulinum Toxin Type A.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Botulinum Toxin Type A.Approved, Vet Approved
PenthienateThe risk or severity of adverse effects can be increased when Penthienate is combined with Botulinum Toxin Type A.Experimental
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type A.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Botulinum Toxin Type A.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Botulinum Toxin Type A.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Botulinum Toxin Type A.Approved
Perphenazine enanthateThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Perphenazine enanthate.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Botulinum Toxin Type A.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Phenacemide is combined with Botulinum Toxin Type A.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Botulinum Toxin Type A.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Phencyclidine is combined with Botulinum Toxin Type A.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Botulinum Toxin Type A.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Phenethylamine is combined with Botulinum Toxin Type A.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Pheneturide is combined with Botulinum Toxin Type A.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Botulinum Toxin Type A.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Botulinum Toxin Type A.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Botulinum Toxin Type A.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Botulinum Toxin Type A.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Botulinum Toxin Type A.Experimental
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Botulinum Toxin Type A.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Phensuximide is combined with Botulinum Toxin Type A.Approved
PhentermineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Botulinum Toxin Type A.Approved, Vet Approved
PhthalylsulfathiazoleThe risk or severity of adverse effects can be increased when Phthalylsulfathiazole is combined with Botulinum Toxin Type A.Experimental
PiclozotanThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Piclozotan.Investigational
PimavanserinThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Botulinum Toxin Type A.Approved
PinazepamThe risk or severity of adverse effects can be increased when Pinazepam is combined with Botulinum Toxin Type A.Experimental
PindololThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Botulinum Toxin Type A.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Botulinum Toxin Type A.Approved
PipenzolateThe risk or severity of adverse effects can be increased when Pipenzolate is combined with Botulinum Toxin Type A.Experimental
PiperidolateThe risk or severity of adverse effects can be increased when Piperidolate is combined with Botulinum Toxin Type A.Experimental
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Botulinum Toxin Type A.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Botulinum Toxin Type A.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Botulinum Toxin Type A.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Botulinum Toxin Type A.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Pirlimycin is combined with Botulinum Toxin Type A.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Botulinum Toxin Type A.Approved
PivagabineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Botulinum Toxin Type A.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Botulinum Toxin Type A.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Botulinum Toxin Type A.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Plazomicin is combined with Botulinum Toxin Type A.Approved, Investigational
PoldineThe risk or severity of adverse effects can be increased when Poldine is combined with Botulinum Toxin Type A.Experimental
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Polymyxin B Sulfate is combined with Botulinum Toxin Type A.Approved, Vet Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Botulinum Toxin Type A.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Botulinum Toxin Type A.Approved
PramipexoleBotulinum Toxin Type A may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Botulinum Toxin Type A.Approved, Illicit
PregabalinThe therapeutic efficacy of Botulinum Toxin Type A can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Pridinol.Experimental
PrifiniumThe risk or severity of adverse effects can be increased when Prifinium is combined with Botulinum Toxin Type A.Experimental
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Botulinum Toxin Type A.Approved, Vet Approved
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Botulinum Toxin Type A.Approved, Investigational
ProcainamideThe risk or severity of adverse effects can be increased when Procainamide is combined with Botulinum Toxin Type A.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Botulinum Toxin Type A.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Botulinum Toxin Type A.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Botulinum Toxin Type A.Approved
ProgabideThe risk or severity of adverse effects can be increased when Progabide is combined with Botulinum Toxin Type A.Approved, Investigational
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Botulinum Toxin Type A.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Botulinum Toxin Type A.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Botulinum Toxin Type A.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Botulinum Toxin Type A.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Botulinum Toxin Type A.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Propiomazine is combined with Botulinum Toxin Type A.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Propiopromazine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Botulinum Toxin Type A.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Botulinum Toxin Type A.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Botulinum Toxin Type A.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Botulinum Toxin Type A.Experimental
PRX-08066The risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with PRX-08066.Investigational
PsilocybineThe risk or severity of adverse effects can be increased when Psilocybine is combined with Botulinum Toxin Type A.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Puromycin is combined with Botulinum Toxin Type A.Experimental
PyrantelThe therapeutic efficacy of Pyrantel can be increased when used in combination with Botulinum Toxin Type A.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Pyrithyldione is combined with Botulinum Toxin Type A.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Botulinum Toxin Type A.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Botulinum Toxin Type A.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Botulinum Toxin Type A.Approved
QuinineThe risk or severity of adverse effects can be increased when Quinine is combined with Botulinum Toxin Type A.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Quinupramine is combined with Botulinum Toxin Type A.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Botulinum Toxin Type A.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Ramosetron.Approved, Investigational
RapacuroniumThe risk or severity of adverse effects can be increased when Rapacuronium is combined with Botulinum Toxin Type A.Approved, Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Botulinum Toxin Type A.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Reboxetine is combined with Botulinum Toxin Type A.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Remacemide is combined with Botulinum Toxin Type A.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Botulinum Toxin Type A.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Botulinum Toxin Type A.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Reposal is combined with Botulinum Toxin Type A.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Botulinum Toxin Type A.Approved, Investigational
RevefenacinThe risk or severity of adverse effects can be increased when Revefenacin is combined with Botulinum Toxin Type A.Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Ribostamycin is combined with Botulinum Toxin Type A.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Riluzole is combined with Botulinum Toxin Type A.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Botulinum Toxin Type A.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Ritanserin.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Rizatriptan.Approved
RociverineThe risk or severity of adverse effects can be increased when Rociverine is combined with Botulinum Toxin Type A.Experimental
RocuroniumThe risk or severity of adverse effects can be increased when Rocuronium is combined with Botulinum Toxin Type A.Approved
RolipramThe risk or severity of adverse effects can be increased when Rolipram is combined with Botulinum Toxin Type A.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Rolitetracycline is combined with Botulinum Toxin Type A.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Botulinum Toxin Type A.Vet Approved
RopiniroleBotulinum Toxin Type A may increase the sedative activities of Ropinirole.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Rosuvastatin is combined with Botulinum Toxin Type A.Approved
RotigotineBotulinum Toxin Type A may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Botulinum Toxin Type A.Approved
SafinamideThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Botulinum Toxin Type A.Withdrawn
SaredutantThe risk or severity of adverse effects can be increased when Saredutant is combined with Botulinum Toxin Type A.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Botulinum Toxin Type A.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Botulinum Toxin Type A.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
SerotoninThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Botulinum Toxin Type A.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Sertraline.Approved
SetrobuvirThe risk or severity of adverse effects can be increased when Setrobuvir is combined with Botulinum Toxin Type A.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Botulinum Toxin Type A.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SildenafilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Botulinum Toxin Type A.Approved, Investigational
Silver sulfadiazineThe risk or severity of adverse effects can be increased when Silver sulfadiazine is combined with Botulinum Toxin Type A.Approved, Vet Approved
SimeprevirThe risk or severity of adverse effects can be increased when Simeprevir is combined with Botulinum Toxin Type A.Approved
SisomicinThe risk or severity of adverse effects can be increased when Sisomicin is combined with Botulinum Toxin Type A.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type A.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Botulinum Toxin Type A.Approved
St. John's WortThe risk or severity of adverse effects can be increased when St. John's Wort is combined with Botulinum Toxin Type A.Approved, Investigational, Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Botulinum Toxin Type A.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Streptomycin is combined with Botulinum Toxin Type A.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Styramate.Experimental
SuccinylcholineThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Botulinum Toxin Type A.Approved
SuccinylsulfathiazoleThe risk or severity of adverse effects can be increased when Succinylsulfathiazole is combined with Botulinum Toxin Type A.Experimental
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Botulinum Toxin Type A.Approved, Investigational
SulfacetamideThe risk or severity of adverse effects can be increased when Sulfacetamide is combined with Botulinum Toxin Type A.Approved
SulfachlorpyridazineThe risk or severity of adverse effects can be increased when Sulfachlorpyridazine is combined with Botulinum Toxin Type A.Vet Approved
SulfacytineThe risk or severity of adverse effects can be increased when Sulfacytine is combined with Botulinum Toxin Type A.Approved
SulfadiazineThe risk or severity of adverse effects can be increased when Sulfadiazine is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
SulfadicramideThe risk or severity of adverse effects can be increased when Sulfadicramide is combined with Botulinum Toxin Type A.Experimental
SulfadimethoxineThe risk or severity of adverse effects can be increased when Sulfadimethoxine is combined with Botulinum Toxin Type A.Approved, Vet Approved
SulfadoxineThe risk or severity of adverse effects can be increased when Sulfadoxine is combined with Botulinum Toxin Type A.Approved, Investigational
SulfaethoxypyridazineThe risk or severity of adverse effects can be increased when Sulfaethoxypyridazine is combined with Botulinum Toxin Type A.Vet Approved
SulfaguanidineThe risk or severity of adverse effects can be increased when Sulfaguanidine is combined with Botulinum Toxin Type A.Experimental
SulfaisodimidineThe risk or severity of adverse effects can be increased when Sulfaisodimidine is combined with Botulinum Toxin Type A.Experimental
SulfamazoneThe risk or severity of adverse effects can be increased when Sulfamazone is combined with Botulinum Toxin Type A.Experimental
SulfamerazineThe risk or severity of adverse effects can be increased when Sulfamerazine is combined with Botulinum Toxin Type A.Approved, Vet Approved
SulfameterThe risk or severity of adverse effects can be increased when Sulfameter is combined with Botulinum Toxin Type A.Approved
SulfamethazineThe risk or severity of adverse effects can be increased when Sulfamethazine is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
SulfamethizoleThe risk or severity of adverse effects can be increased when Sulfamethizole is combined with Botulinum Toxin Type A.Approved, Investigational, Vet Approved
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Botulinum Toxin Type A.Approved
SulfamethoxypyridazineThe risk or severity of adverse effects can be increased when Sulfamethoxypyridazine is combined with Botulinum Toxin Type A.Experimental
SulfametomidineThe risk or severity of adverse effects can be increased when Sulfametomidine is combined with Botulinum Toxin Type A.Experimental
SulfametopyrazineThe risk or severity of adverse effects can be increased when Sulfametopyrazine is combined with Botulinum Toxin Type A.Approved, Withdrawn
SulfamoxoleThe risk or severity of adverse effects can be increased when Sulfamoxole is combined with Botulinum Toxin Type A.Approved
SulfanilamideThe risk or severity of adverse effects can be increased when Sulfanilamide is combined with Botulinum Toxin Type A.Approved
SulfanitranThe risk or severity of adverse effects can be increased when Sulfanitran is combined with Botulinum Toxin Type A.Vet Approved
SulfaperinThe risk or severity of adverse effects can be increased when Sulfaperin is combined with Botulinum Toxin Type A.Experimental
SulfaphenazoleThe risk or severity of adverse effects can be increased when Sulfaphenazole is combined with Botulinum Toxin Type A.Approved
SulfapyridineThe risk or severity of adverse effects can be increased when Sulfapyridine is combined with Botulinum Toxin Type A.Approved
SulfaquinoxalineThe risk or severity of adverse effects can be increased when Sulfaquinoxaline is combined with Botulinum Toxin Type A.Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Botulinum Toxin Type A.Approved
SulfathiazoleThe risk or severity of adverse effects can be increased when Sulfathiazole is combined with Botulinum Toxin Type A.Approved, Vet Approved
SulfathioureaThe risk or severity of adverse effects can be increased when Sulfathiourea is combined with Botulinum Toxin Type A.Experimental
SulfatolamideThe risk or severity of adverse effects can be increased when Sulfatolamide is combined with Botulinum Toxin Type A.Experimental
SulfisoxazoleThe risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Botulinum Toxin Type A.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Botulinum Toxin Type A.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Sulthiame is combined with Botulinum Toxin Type A.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Botulinum Toxin Type A.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Botulinum Toxin Type A.Approved, Investigational
SuvorexantBotulinum Toxin Type A may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Talbutal is combined with Botulinum Toxin Type A.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Talopram.Experimental
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Botulinum Toxin Type A.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type A.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Tegaserod.Approved, Investigational, Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Botulinum Toxin Type A.Approved, Investigational
TerfenadineThe risk or severity of adverse effects can be increased when Terfenadine is combined with Botulinum Toxin Type A.Approved, Withdrawn
TetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Botulinum Toxin Type A.Approved, Vet Approved
TetraethylammoniumThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Tetraethylammonium.Experimental, Investigational
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Botulinum Toxin Type A.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Botulinum Toxin Type A.Investigational
ThalidomideBotulinum Toxin Type A may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Botulinum Toxin Type A.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Botulinum Toxin Type A.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Thiopropazate is combined with Botulinum Toxin Type A.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Botulinum Toxin Type A.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Botulinum Toxin Type A.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Botulinum Toxin Type A.Approved
ThonzylamineThe risk or severity of adverse effects can be increased when Thonzylamine is combined with Botulinum Toxin Type A.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Botulinum Toxin Type A.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Botulinum Toxin Type A.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Botulinum Toxin Type A.Approved, Investigational
Tiemonium iodideThe risk or severity of adverse effects can be increased when Tiemonium iodide is combined with Botulinum Toxin Type A.Experimental
TigecyclineThe risk or severity of adverse effects can be increased when Tigecycline is combined with Botulinum Toxin Type A.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Botulinum Toxin Type A.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Botulinum Toxin Type A.Experimental
TimepidiumThe risk or severity of adverse effects can be increased when Timepidium is combined with Botulinum Toxin Type A.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Botulinum Toxin Type A.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Botulinum Toxin Type A.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Tobramycin is combined with Botulinum Toxin Type A.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Tofisopam is combined with Botulinum Toxin Type A.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Botulinum Toxin Type A.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Botulinum Toxin Type A.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Tolperisone.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Botulinum Toxin Type A.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Botulinum Toxin Type A.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Botulinum Toxin Type A.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Botulinum Toxin Type A.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Tramiprosate is combined with Botulinum Toxin Type A.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Botulinum Toxin Type A.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Botulinum Toxin Type A.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Botulinum Toxin Type A.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Botulinum Toxin Type A.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Botulinum Toxin Type A.Approved
TriclofosThe risk or severity of adverse effects can be increased when Triclofos is combined with Botulinum Toxin Type A.Withdrawn
TridihexethylThe risk or severity of adverse effects can be increased when Tridihexethyl is combined with Botulinum Toxin Type A.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Botulinum Toxin Type A.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Botulinum Toxin Type A.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Botulinum Toxin Type A.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Botulinum Toxin Type A.Approved
TrimebutineThe risk or severity of adverse effects can be increased when Trimebutine is combined with Botulinum Toxin Type A.Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Botulinum Toxin Type A.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Botulinum Toxin Type A.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Botulinum Toxin Type A.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Botulinum Toxin Type A.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Botulinum Toxin Type A.Approved, Investigational
TropisetronThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Tropisetron.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Botulinum Toxin Type A.Approved
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Botulinum Toxin Type A.Approved
UrapidilThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Urapidil.Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Vabicaserin.Investigational
ValerianThe risk or severity of adverse effects can be increased when Valerian is combined with Botulinum Toxin Type A.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Valnoctamide is combined with Botulinum Toxin Type A.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Botulinum Toxin Type A.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Valpromide is combined with Botulinum Toxin Type A.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Botulinum Toxin Type A.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Botulinum Toxin Type A.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Botulinum Toxin Type A.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Botulinum Toxin Type A.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Botulinum Toxin Type A.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Viloxazine is combined with Botulinum Toxin Type A.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Vinbarbital is combined with Botulinum Toxin Type A.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Botulinum Toxin Type A.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Botulinum Toxin Type A.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Vinylbital is combined with Botulinum Toxin Type A.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Botulinum Toxin Type A.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Wortmannin.Experimental
XipamideThe risk or severity of adverse effects can be increased when Xipamide is combined with Botulinum Toxin Type A.Experimental
XP19986The risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Botulinum Toxin Type A.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Botulinum Toxin Type A.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Botulinum Toxin Type A.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Botulinum Toxin Type A.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Botulinum Toxin Type A.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Zolmitriptan.Approved, Investigational
ZolpidemBotulinum Toxin Type A may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Botulinum Toxin Type A.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Botulinum Toxin Type A.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Botulinum Toxin Type A.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Montecucco C, Molgo J: Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005 Jun;5(3):274-9. [PubMed:15907915]
  2. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22;53(7):1431-8. [PubMed:10534247]
  3. Shukla HD, Sharma SK: Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31(1):11-8. [PubMed:15839401]
  4. Eisenach JH, Atkinson JL, Fealey RD: Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clin Proc. 2005 May;80(5):657-66. [PubMed:15887434]
  5. Schurch B, Corcos J: Botulinum toxin injections for paediatric incontinence. Curr Opin Urol. 2005 Jul;15(4):264-7. [PubMed:15928517]
External Links
UniProt
P10845
Genbank
X52066
KEGG Drug
D00783
KEGG Compound
C07946
PubChem Substance
46505347
Therapeutic Targets Database
DAP001298
PharmGKB
PA164754825
RxList
RxList Drug Page
Wikipedia
Botox
ATC Codes
M03AX01 — Botulinum toxin
AHFS Codes
  • 92:92.00 — Other Miscellaneous Therapeutic Agents
FDA label
Download (115 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentBladder Pain Syndrome1
0CompletedTreatmentStrokes1
0Not Yet RecruitingTreatmentGummy Smile Due to Hypermobile Upper Lip1
0RecruitingTreatmentComplex Regional Pain Syndrome (CRPS)1
0RecruitingTreatmentSecondary Headache Disorder1
0TerminatedTreatmentNeurocostal neuralgia1
0WithdrawnDiagnosticBenign Prostatic Hyperplasia (BPH) / Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS) / Prostate Cancer1
1Active Not RecruitingTreatmentPruritus1
1CompletedOtherPsoriasis Vulgaris (Plaque Psoriasis)1
1CompletedTreatmentBMI >30 kg/m22
1CompletedTreatmentCerebral Palsy (CP) / Spasticity1
1CompletedTreatmentDry Eye Syndromes1
1CompletedTreatmentHyperhidrosis1
1CompletedTreatmentKnee Osteoarthritis (Knee OA)1
1CompletedTreatmentScrotal Pain1
1CompletedTreatmentVaginismus1
1CompletedTreatmentVasculogenic Erectile Dysfunction1
1CompletedTreatmentWound; Abdomen, Abdominal Wall1
1Not Yet RecruitingTreatmentHyperhidrosis1
1Not Yet RecruitingTreatmentParkinson's Disease (PD)1
1RecruitingBasic ScienceHealthy Volunteers2
1RecruitingTreatmentBotulinum Toxins, Type A / Plantar Fascitis1
1RecruitingTreatmentCervical Pain / Low Back Pain (LBP)1
1RecruitingTreatmentDepression / Parkinson's Disease (PD)1
1RecruitingTreatmentMyofascial Pain Syndromes / Myofascial Trigger Point Pain / Trigger Point Pain, Myofascial1
1RecruitingTreatmentOveractive Bladder1
1Unknown StatusTreatmentThoracic Outlet Syndrome1
1WithdrawnTreatmentBruxism / Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint / Temporomandibular Joint Disorders / Temporomandibular Joint Dysfunction Syndrome1
1WithdrawnTreatmentTorticollis1
1, 2Active Not RecruitingPreventionNonvalvular Atrial Fibrillation1
1, 2Active Not RecruitingTreatmentHeadache Disorders / Trigeminal Neuralgia (TN)1
1, 2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
1, 2CompletedTreatmentCervical Dystonia / Refractory Cervicothoracic Myofascial Pain Syndrome (CMPS)1
1, 2CompletedTreatmentCluster Headache1
1, 2CompletedTreatmentDetrusor Hyperreflexia / Detrusor Instability / Overactive Bladder1
1, 2CompletedTreatmentMigraine Disorders1
1, 2CompletedTreatmentOral Dystonia / Tardive Dystonia1
1, 2CompletedTreatmentOsteoarthritis (OA)1
1, 2Not Yet RecruitingTreatmentAbnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus / Cervical Dystonia Adults 1
1, 2Not Yet RecruitingTreatmentChronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer1
1, 2Not Yet RecruitingTreatmentIncreased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors / Upper Limb Spasticity Unilaterally in Adults With History of Stroke1
1, 2RecruitingTreatmentCleft Lip / Cleft Palates / Scarring1
1, 2RecruitingTreatmentCluster Headache1
1, 2TerminatedTreatmentEmpty Nose Syndrome / Rhinitis, Atrophic1
1, 2Unknown StatusTreatmentUrge Urinary Incontinence1
2Active Not RecruitingTreatmentDisease, Chronic / Nasal Polyposis / Rhinitis1
2Active Not RecruitingTreatmentObesity, Morbid1
2Active Not RecruitingTreatmentRaynaud's Disease1
2Active Not RecruitingTreatmentTremors1
2CompletedPreventionMigraines1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS) / Sialorrhea1
2CompletedTreatmentAnal Fissures1
2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)3
2CompletedTreatmentBlepharospasm1
2CompletedTreatmentBotulinum Toxins, Type A1
2CompletedTreatmentBurning Mouth Syndrome1
2CompletedTreatmentCarpal Tunnel Syndrome (CTS)1
2CompletedTreatmentCerebral Palsy (CP)1
2CompletedTreatmentCerebral Palsy (CP) / Equine and Equinovarus Foot Deformation / Spastic Paraplegia and Hemiparesis1
2CompletedTreatmentCerebral Palsy (CP) / Muscle Spasticity1
2CompletedTreatmentCervical Dystonia2
2CompletedTreatmentCervicogenic Headaches1
2CompletedTreatmentChronic Pain Syndrome / Prostatitis1
2CompletedTreatmentChronic Testicular Pain1
2CompletedTreatmentCrows Feet / Facial Wrinkles / Lateral Canthal Lines3
2CompletedTreatmentCrows Feet / Lateral Canthal Lines1
2CompletedTreatmentCutaneous Leiomyomas / Hereditary Leiomyomatosis and Renal Cell Cancer1
2CompletedTreatmentDementias / Paratonia1
2CompletedTreatmentDepression1
2CompletedTreatmentDetrusor Muscle Hyperactivity1
2CompletedTreatmentDiabetes Mellitus (DM) / Muscle Cramps Aggravated1
2CompletedTreatmentEssential Tremor of the Upper Limbs1
2CompletedTreatmentFacial Rhytids1
2CompletedTreatmentGlabellar Frown Lines3
2CompletedTreatmentHyperhidrosis1
2CompletedTreatmentInterstitial Cystitis1
2CompletedTreatmentLacrimation increased1
2CompletedTreatmentLateral Canthal Lines1
2CompletedTreatmentLow Anterior Resection Syndrome / Rectal Carcinoma1
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2CompletedTreatmentMasticatory Muscles, Hypertrophy of1
2CompletedTreatmentMotor Neurone Disease / Muscle Spasticity / Strokes1
2CompletedTreatmentMuscle Contracture / Muscle Spasticity / Strokes1
2CompletedTreatmentMuscle Spasticity / Strokes2
2CompletedTreatmentMyofascial Pain Syndromes2
2CompletedTreatmentOsteoarthritis (OA)1
2CompletedTreatmentOveractive Bladder3
2CompletedTreatmentOveractive Bladder / Urinary Incontinence (UI)1
2CompletedTreatmentPain of the knee1
2CompletedTreatmentParkinson / Tremors1
2CompletedTreatmentPostherpetic Neuralgia1
2CompletedTreatmentProctalgia1
2CompletedTreatmentRestless Legs Syndrome (RLS)1
2CompletedTreatmentSialorrhea1
2CompletedTreatmentSkin Aging1
2CompletedTreatmentStomach Neoplasms1
2CompletedTreatmentThoracic Outlet Syndrome1
2Enrolling by InvitationPreventionPost-operative Excessive Scarring1
2Enrolling by InvitationTreatmentScrotal Pain1
2Not Yet RecruitingTreatmentBenign Masseteric Hypertrophy1
2Not Yet RecruitingTreatmentChronic Scar Pain1
2Not Yet RecruitingTreatmentFunctional Popliteal Artery Entrapment Syndrome / Popliteal artery entrapment syndrome1
2Not Yet RecruitingTreatmentGroin Injury / Tendinopathy1
2Not Yet RecruitingTreatmentPeripheral Neuropathy Due to Chemotherapy1
2Not Yet RecruitingTreatmentTemporo-Myofascial Disorder1
2RecruitingSupportive CareOesophageal Carcinoma1
2RecruitingTreatmentAtrial Flutter1
2RecruitingTreatmentBenign Prostatic Hyperplasia (BPH) / Lower Urinary Track Symptoms1
2RecruitingTreatmentBladder Pain Syndrome1
2RecruitingTreatmentBorderline Personality Disorder (BPD)1
2RecruitingTreatmentCerebral Palsy, Spastic / Pain1
2RecruitingTreatmentCervical Dystonia1
2RecruitingTreatmentDisease, Chronic / Migraine Disorders1
2RecruitingTreatmentDystonias1
2RecruitingTreatmentFacial Pain1
2RecruitingTreatmentHallux Abductovalgus1
2RecruitingTreatmentHyperhidrosis1
2RecruitingTreatmentHypertrophic Scars1
2RecruitingTreatmentHypertrophy of Masseter Muscle1
2RecruitingTreatmentMigraine Disorders / Migrainous Headache / Pediatrics1
2RecruitingTreatmentNeuropathic Back Pain / Spinal Cord Injuries (SCI)1
2RecruitingTreatmentObstructed Defecation Syndrome (ODS)1
2RecruitingTreatmentOveractive Bladder With Urinary Incontinence / Urinary Incontinence (UI)1
2RecruitingTreatmentParkinson's Disease (PD)1
2RecruitingTreatmentPeyronie's Disease1
2RecruitingTreatmentPost-Operative Pain1
2RecruitingTreatmentPremature Ejaculation1
2RecruitingTreatmentRotator Cuff Tear Arthropathy1
2RecruitingTreatmentTremor, Essential1
2RecruitingTreatmentTrigeminal Neuralgia (TN)1
2RecruitingTreatmentVulvodynia1
2TerminatedTreatmentAcne Vulgaris1
2TerminatedTreatmentAllodynia / Pain, Neuropathic1
2TerminatedTreatmentBlepharospasm1
2TerminatedTreatmentCerebral Palsy (CP)1
2TerminatedTreatmentHabitual Snoring1
2TerminatedTreatmentLower Back Pain1
2TerminatedTreatmentNeurogenic Bladder Dysfunction Nos / Spinal Cord Injuries (SCI)1
2TerminatedTreatmentNew Daily Persistent Headache1
2TerminatedTreatmentOveractive Bladder2
2TerminatedTreatmentPain1
2Unknown StatusPreventionScarring1
2Unknown StatusTreatmentArthritis / Pain1
2Unknown StatusTreatmentEpidermolysis Bullosa Simplex1
2Unknown StatusTreatmentHemifacial Spasm1
2Unknown StatusTreatmentRosaceas1
2WithdrawnTreatmentAmyotrophic Lateral Sclerosis (ALS) / Parkinson's Disease (PD)1
2WithdrawnTreatmentContact Ulcer of Vocal Folds / Granuloma / Granuloma of Vocal Cords / Granuloma, Laryngeal1
2WithdrawnTreatmentLower Urinary Tract Symptoms (LUTS) / Prostate Cancer / Radioactive Seed Implantation1
2WithdrawnTreatmentNeuroma1
2WithdrawnTreatmentOveractive Bladder / Urinary Incontinence (UI)1
2, 3CompletedPreventionScarring1
2, 3CompletedTreatmentBenign Prostatic Enlargement (BPE) / Benign Prostatic Hyperplasia (BPH)1
2, 3CompletedTreatmentFowler's Syndrome / Urinary Retention1
2, 3CompletedTreatmentPlantar Fasciitis, Chronic1
2, 3CompletedTreatmentRecalcitrant Alopecia Totalis / Recalcitrant Alopecia Universalis1
2, 3CompletedTreatmentRefractory Migraine1
2, 3CompletedTreatmentSialorrhea1
2, 3Not Yet RecruitingTreatmentBase-of-thumb Osteoarthritis1
2, 3Not Yet RecruitingTreatmentEpidermolysis Bullosa Simplex1
2, 3RecruitingTreatmentBlepharospasm1
2, 3RecruitingTreatmentCrows Feet Lines1
2, 3RecruitingTreatmentErectile Dysfunction (ED) / Sexual Dysfunctions1
2, 3TerminatedTreatmentPrimary Focal Hyperhidrosis of the Hands1
2, 3Unknown StatusPreventionForward Head Posture With Associated Episodic Headache Disorder1
2, 3Unknown StatusTreatmentCerebral Palsy (CP) / Sialorrhea1
2, 3Unknown StatusTreatmentLower Limb Spasticity After Stroke1
2, 3Unknown StatusTreatmentNon-relaxing Puborectalis Syndrome1
2, 3Unknown StatusTreatmentOveractive Bladder1
3Active Not RecruitingTreatmentCOMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO1
3Active Not RecruitingTreatmentCerebral Palsy (CP) / Chronic Troublesome Sialorrhea / Disability, Intellectual / Strokes / Traumatic Brain Injury (TBI)1
3Active Not RecruitingTreatmentCerebral Palsy (CP) / Muscle Spasticity / Pediatrics / Strokes1
3Active Not RecruitingTreatmentUpper Limb Spasticity (Altered Skeletal Muscle Performance) in Children1
3Active Not RecruitingTreatmentUrinary Incontinence (UI)1
3CompletedNot AvailableAging1
3CompletedSupportive CareBRCA1 Mutations / BRCA2 Mutation / Breast Diseases / Cancer, Breast / Neoplasms / Postoperative pain1
3CompletedSupportive CareStroke With Hemiparesis1
3CompletedTreatmentAllodynia / Headaches1
3CompletedTreatmentBilateral Blepharospasm (BEB)1
3CompletedTreatmentBlepharospasm2
3CompletedTreatmentCanthal Lines1
3CompletedTreatmentCerebral Palsy (CP)1
3CompletedTreatmentCerebral Palsy (CP) / Children / Muscle Spasticity2
3CompletedTreatmentCerebral Palsy (CP) / Muscle Spasticity / Pediatrics2
3CompletedTreatmentCerebral Palsy (CP) / Muscle Spasticity / Pediatrics / Strokes1
3CompletedTreatmentCerebral Palsy (CP) / Spasticity1
3CompletedTreatmentCerebrovascular Accidents3
3CompletedTreatmentCervical Dystonia5
3CompletedTreatmentChronic Low-back Pain1
3CompletedTreatmentChronic Troublesome Sialorrhea / Parkinson's Disease (PD) / Post-stroke / Traumatic Brain Injury (TBI)1
3CompletedTreatmentCrow's Feet Lines / Facial Rhytides / Glabellar Lines2
3CompletedTreatmentCrow's Feet Lines / Frown Lines / Glabellar Lines / Upper Facial Rhytides1
3CompletedTreatmentCrow's Feet Lines / Lateral Canthal Lines1
3CompletedTreatmentCrow's Feet Lines / Lateral Canthus Rhytides2
3CompletedTreatmentDisseminated Sclerosis / Neurogenic Bladder Dysfunction / Urinary Incontinence (UI)1
3CompletedTreatmentDisseminated Sclerosis / Tremors1
3CompletedTreatmentEssential Blepharospasm2
3CompletedTreatmentFacial Rhytides / Glabellar Rhytides1
3CompletedTreatmentForehead Rhytides / Glabellar Rhytides1
3CompletedTreatmentFrown Lines Between the Eyebrows / Glabellar Rhytides1
3CompletedTreatmentGlabellar Frown Lines1
3CompletedTreatmentGlabellar Lines4
3CompletedTreatmentGlabellar Lines / Moderate to Severe Glabellar Lines1
3CompletedTreatmentGlabellar Rhytides2
3CompletedTreatmentHyperhidrosis1
3CompletedTreatmentLateral Epicondylitis1
3CompletedTreatmentLateral Periorbital Wrinkles1
3CompletedTreatmentLeg Spasticity1
3CompletedTreatmentLow Back Pain (LBP)1
3CompletedTreatmentLower Extremity Deformities, Congenital / Unequal Length of Limbs; Congenital1
3CompletedTreatmentLower Limb Spasticity Due to Cerebral Palsy1
3CompletedTreatmentLower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy1
3CompletedTreatmentMigraine Disorders3
3CompletedTreatmentModerate to Severe Glabellar Line1
3CompletedTreatmentMuscle Spasticity1
3CompletedTreatmentMyofascial Pain Syndromes1
3CompletedTreatmentNervous System Disorders2
3CompletedTreatmentNeurogenic Detrusor Overactivity1
3CompletedTreatmentNotalgia Paresthetica1
3CompletedTreatmentOther Infantile Cerebral Palsy1
3CompletedTreatmentOveractive Bladder5
3CompletedTreatmentOveractive Bladder / Urinary Incontinence (UI)2
3CompletedTreatmentPost-stroke Spasticity of the Lower Limb1
3CompletedTreatmentPost-stroke Spasticity of the Upper Limb1
3CompletedTreatmentPost-stroke Upper Limb Spasticity1
3CompletedTreatmentRaynaud's Syndrome / Scleroderma1
3CompletedTreatmentRefractory Urge Urinary Incontinence / Urinary Incontinence, Urge1
3CompletedTreatmentSkin Aging5
3CompletedTreatmentSpasticity1
3CompletedTreatmentSpasticity Post-Traumatic Brain Injury / Spasticity, Post-Stroke1
3CompletedTreatmentSpasticity of the Upper and Lower Limb Due to Cerebral Causes1
3CompletedTreatmentSpasticity, Post-Stroke1
3CompletedTreatmentSpasticity / Strokes2
3CompletedTreatmentStrabismus1
3CompletedTreatmentStrokes1
3CompletedTreatmentUpper Limb Spasticity1
3CompletedTreatmentFacial fine wrinkling1
3Enrolling by InvitationTreatmentChronic Migraine1
3Enrolling by InvitationTreatmentOveractive Bladder1
3Not Yet RecruitingTreatmentAcquired Esotropia1
3Not Yet RecruitingTreatmentCerebral Palsy (CP)1
3Not Yet RecruitingTreatmentCerebrovascular Accidents1
3Not Yet RecruitingTreatmentObstetrical Brachial Plexus Palsy1
3Not Yet RecruitingTreatmentTrigeminal Neuropathy, Traumatic1
3RecruitingPreventionIntercanthal Distance Ratio / Scarring1
3RecruitingTreatmentCerebral Palsy (CP)2
3RecruitingTreatmentCerebrovascular Accidents1
3RecruitingTreatmentCrow's Feet Lines2
3RecruitingTreatmentDisseminated Sclerosis / Spasticity, Muscle1
3RecruitingTreatmentHyperhidrosis / Residual Limbs1
3RecruitingTreatmentLateral Epicondylitis1
3RecruitingTreatmentMuscle Spasticity1
3RecruitingTreatmentMyofascial Pain Syndrome / Pain Syndrome / Pain, Head / Temporomandibular Disorders1
3RecruitingTreatmentOveractive Bladder1
3RecruitingTreatmentOveractive Bladder / Urinary Incontinence (UI)2
3RecruitingTreatmentStrokes1
3RecruitingTreatmentTrigeminal Neuralgia (TN)1
3RecruitingTreatmentUrinary Bladder, Overactive / Urinary Incontinence (UI)1
3RecruitingTreatmentUrinary Incontinence (UI)1
3RecruitingTreatmentVestibulodynia1
3RecruitingTreatmentVulvodynia1
3TerminatedTreatmentChronic Post Traumatic Headache1
3TerminatedTreatmentChronic Prostatitis With Chronic Pelvic Pain Syndrome / Prostatitis1
3TerminatedTreatmentDetrusor Hyperreflexia / Overactive Bladder / Urge Incontinence / Urinary Incontinence (UI) / Urinary Urge Incontinence1
3TerminatedTreatmentDetrusor Overactivity / Urge Urinary Incontinence / Urinary Incontinence (UI) / Urination urgency of1
3TerminatedTreatmentLower Urinary Tract Discomfort / Stent Pain1
3TerminatedTreatmentMuscle Spasticity / Strokes1
3TerminatedTreatmentOveractive Bladder1
3TerminatedTreatmentPatellofemoral Pain Syndrome1
3TerminatedTreatmentSkin Aging1
3Unknown StatusTreatmentHemiplegic Patients Post-AVC1
3Unknown StatusTreatmentOveractive Bladder1
3Unknown StatusTreatmentScarring1
3Unknown StatusTreatmentFacial fine wrinkling1
3WithdrawnOtherNeurocostal neuralgia / Pain Due to Certain Specified Procedures / Pain, Neuropathic1
3WithdrawnPreventionMigraine Disorders2
3WithdrawnTreatmentMuscle Spasticity / Strokes1
4Active Not RecruitingTreatmentBlepharospasm / Botulinum Toxins, Type A / Hemifacial Spasm1
4Active Not RecruitingTreatmentChronic Idiopathic Constipation / Functional Constipation1
4Active Not RecruitingTreatmentParkinson's Disease (PD)1
4Active Not RecruitingTreatmentUrinary Bladder, Overactive / Urinary Incontinence (UI)1
4CompletedNot AvailableHealthy Subjects, Only With Wrinkles on Forehead1
4CompletedNot AvailableMigraine Disorders1
4CompletedNot AvailableUrinary Bladder, Overactive1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedPreventionMigraine Disorders2
4CompletedPreventionOveractive Bladder / Painful Bladder Syndrome (PBS) / Urinary Bladder, Neurogenic / Urinary Urge Incontinence1
4CompletedPreventionStrokes / Upper Limb Spasticity1
4CompletedTreatmentAging1
4CompletedTreatmentBlepharospasm1
4CompletedTreatmentBrain Injury / Spasticity Secondary to Either a Disorder or Trauma / Spinal Cord Injuries (SCI) / Strokes / Tumors1
4CompletedTreatmentBrain Injury / Spasticity / Strokes1
4CompletedTreatmentBrow Ptosis1
4CompletedTreatmentBrow Ptosis / Lid Ptosis1
4CompletedTreatmentCerebral Palsy (CP)1
4CompletedTreatmentCerebral Palsy and Botulinum Toxin1
4CompletedTreatmentCerebrovascular Accidents / Muscle Spasticity2
4CompletedTreatmentCervical Dystonia4
4CompletedTreatmentChronic Migraine5
4CompletedTreatmentCrow's Feet Lines / Facial Rhytides / Glabellar Lines / Nasolabial Folds1
4CompletedTreatmentDiabetic Polyneuropathies / Other Polyneuropathies / Postherpetic Neuralgia1
4CompletedTreatmentDisseminated Sclerosis / Muscle Spasticity1
4CompletedTreatmentEsotropia / Exotropia1
4CompletedTreatmentEssential Blepharospasm2
4CompletedTreatmentFacial Asymmetry / Facial Nerve Injuries / Facial Paresis Associated With Facial Nerve Dysfunction / Synkinesis1
4CompletedTreatmentFacial Rhytides1
4CompletedTreatmentGlabellar Frown Lines3
4CompletedTreatmentGlabellar Furrows1
4CompletedTreatmentGlabellar Lines1
4CompletedTreatmentGlabellar Rhytides1
4CompletedTreatmentHallux Valgus1
4CompletedTreatmentHyperhidrosis2
4CompletedTreatmentInterstitial Cystitis1
4CompletedTreatmentInterstitial Cystitis / Painful Bladder Syndrome (PBS)1
4CompletedTreatmentIntrinsic Aging of Skin / Solar Elastosis1
4CompletedTreatmentMigraine Disorders2
4CompletedTreatmentMild to Moderate Temporal Atrophy / Moderate to Severe Glabellar Rhytids / Moderate to Severe Periorbital Rhytids1
4CompletedTreatmentMuscle Spasticity1
4CompletedTreatmentOveractive Bladder1
4CompletedTreatmentOveractive Bladder / Urinary Incontinence (UI)1
4CompletedTreatmentPain, Neuropathic / Spinal Cord Injuries (SCI)1
4CompletedTreatmentPlantar Fascitis1
4CompletedTreatmentSkin Aging1
4CompletedTreatmentSpasmodic Torticollis1
4CompletedTreatmentSpastic Hemiplegia1
4CompletedTreatmentSpastic Hemiplegia / Spasticity as Sequela of Stroke / Strokes1
4CompletedTreatmentSpasticity1
4CompletedTreatmentStroke Rehabilitation / Stroke Rehabilitation Spasticity Management1
4CompletedTreatmentSun-induced Wrinkles1
4CompletedTreatmentTorticollis1
4CompletedTreatmentUpper Limb Spasticity1
4CompletedTreatmentWrinkles in Frontal Area1
4CompletedTreatmentFacial fine wrinkling1
4Not Yet RecruitingTreatmentAchalasia1
4Not Yet RecruitingTreatmentActivity / Pain1
4Not Yet RecruitingTreatmentEquinovarus; Acquired1
4Not Yet RecruitingTreatmentOveractive Bladder / Overactive Bladder Syndrome / Urinary Bladder, Overactive / Urinary Frequency/Urgency / Urinary Incontinence (UI) / Urination urgency of1
4RecruitingBasic ScienceMigraines1
4RecruitingOtherMuscle Spasticity / Strokes1
4RecruitingPreventionOther Degenerative Disorders of Eyelid and Periocular Area1
4RecruitingTreatmentBreast Diseases / Neoplasms / Neoplasms by Site / Neoplasms, Breast / Skin Diseases1
4RecruitingTreatmentBrow Lifting1
4RecruitingTreatmentCerebral Palsy (CP) / Muscle Spasticity1
4RecruitingTreatmentKnee Osteoarthritis (Knee OA)1
4RecruitingTreatmentMixed Urinary Incontinence / Stress Urinary Incontinence (SUI) / Urgency Incontinence1
4RecruitingTreatmentPain, Face1
4RecruitingTreatmentPainful Intercourse / Pelvic Floor Dysfunctions / Pelvic Pain1
4RecruitingTreatmentRaynaud's Phenomenon1
4RecruitingTreatmentScarring1
4RecruitingTreatmentSpasticity1
4RecruitingTreatmentSpinal Cord Injuries (SCI) / Urinary Bladder, Overactive1
4TerminatedTreatmentAnxiety Disorder Social / Feeling Anxious1
4TerminatedTreatmentArthritis Multiple Joint / Basal Thumb Joint Arthritis / Basilar Joint Arthritis / Carpometacarpal Arthritis / Trapeziometacarpal Arthritis1
4TerminatedTreatmentChronic Male Pelvic Pain Syndrome1
4TerminatedTreatmentLow Back Pain (LBP)1
4TerminatedTreatmentParkinson's Disease (PD)1
4TerminatedTreatmentSpasmodic Torticollis1
4Unknown StatusPreventionAutonomic Dysreflexia1
4Unknown StatusTreatmentBruxism1
4Unknown StatusTreatmentCatocholamine Induced Finger Necrosis1
4Unknown StatusTreatmentChronic Low Back Pain (CLBP)1
4Unknown StatusTreatmentElastosis Senilis / Skin Aging1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentMuscle Spasticity1
4Unknown StatusTreatmentOveractive Detrusor1
4Unknown StatusTreatmentSleep Bruxism1
4WithdrawnTreatmentFoot Deformities / Leg Length Inequality1
4WithdrawnTreatmentGraves Ophthalmopathy1
Not AvailableActive Not RecruitingNot AvailableDysphonia1
Not AvailableActive Not RecruitingTreatmentFacial Flushing1
Not AvailableActive Not RecruitingTreatmentHeadaches1
Not AvailableActive Not RecruitingTreatmentIdiopathic Clubfoot (Talipes Equinovarus)1
Not AvailableActive Not RecruitingTreatmentMyofascial Pelvic Pain1
Not AvailableActive Not RecruitingTreatmentPelvic Pain1
Not AvailableActive Not RecruitingTreatmentFacial fine wrinkling1
Not AvailableCompletedNot AvailableBlepharospasm / Cervical Dystonia1
Not AvailableCompletedNot AvailableCerebral Palsy (CP)1
Not AvailableCompletedNot AvailableChronic Migraine, Headaches1
Not AvailableCompletedNot AvailableCrow's Feet Lines / Lateral Canthal Lines1
Not AvailableCompletedNot AvailableFacial Rhytides1
Not AvailableCompletedNot AvailableGlabellar Lines1
Not AvailableCompletedNot AvailableGlabellar Lines / Hyperhidrosis / Muscle Spasticity1
Not AvailableCompletedNot AvailableHeadaches / Migraine Disorders1
Not AvailableCompletedNot AvailableLower Limb Spasticity1
Not AvailableCompletedNot AvailableMigraine Disorders1
Not AvailableCompletedNot AvailableMumps1
Not AvailableCompletedNot AvailableMuscle Spasticity2
Not AvailableCompletedNot AvailableOveractive Bladder / Urinary Incontinence (UI)1
Not AvailableCompletedNot AvailableSkin Laxity1
Not AvailableCompletedNot AvailableSpasticity, Post-Stroke1
Not AvailableCompletedNot AvailableTorticollis1
Not AvailableCompletedNot AvailableUrinary Bladder, Neurogenic / Urinary Bladder, Overactive1
Not AvailableCompletedNot AvailableUrinary Bladder, Overactive / Urinary Incontinence (UI)2
Not AvailableCompletedNot AvailableUrinary Incontinence (UI)1
Not AvailableCompletedDiagnosticBotulinum Toxins, Type A / Normal, Healthy Volunteers / Strength, Muscle1
Not AvailableCompletedHealth Services ResearchHealthy Volunteers1
Not AvailableCompletedHealth Services ResearchMuscle Spasticity / Strokes1
Not AvailableCompletedPreventionHerpes Labialis1
Not AvailableCompletedPreventionPost Traumatic Stiffness1
Not AvailableCompletedSupportive CarePain1
Not AvailableCompletedTreatmentAchalasia, Esophageal1
Not AvailableCompletedTreatmentAxillary Hyperhidrosis1
Not AvailableCompletedTreatmentCerebral Palsy (CP) / Muscle Spasticity1
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / Pain, Neuropathic1
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / Peripheral Neuropathy / Plantar Ulcers1
Not AvailableCompletedTreatmentEpicondylitis, Lateral Humeral / Lateral Epicondylitis1
Not AvailableCompletedTreatmentFacial Paralysis1
Not AvailableCompletedTreatmentFacial Rhytides / Glabellar Frown Lines1
Not AvailableCompletedTreatmentFacial Wrinkles1
Not AvailableCompletedTreatmentHIV Posterior Cheek Enlargement1
Not AvailableCompletedTreatmentHyperhidrosis1
Not AvailableCompletedTreatmentIdiopathic Clubfoot (Talipes Equinovarus)1
Not AvailableCompletedTreatmentKeratoconus1
Not AvailableCompletedTreatmentNon-neurogenic / Urinary Urge Incontinence1
Not AvailableCompletedTreatmentPain1
Not AvailableCompletedTreatmentPost-stroke Shoulder Pain and Spasticity1
Not AvailableCompletedTreatmentPrimary Axillary Hyperhidrosis1
Not AvailableCompletedTreatmentRaynaud's Syndrome1
Not AvailableCompletedTreatmentSkin Wrinklings1
Not AvailableCompletedTreatmentSpastic Equinovarus1
Not AvailableCompletedTreatmentSubacute Cervical Pain / Subacute Upper Back Pain1
Not AvailableCompletedTreatmentTremor, Essential1
Not AvailableCompletedTreatmentUrinary Incontinence (UI)1
Not AvailableCompletedTreatmentVaginismus1
Not AvailableEnrolling by InvitationNot AvailableUnilateral Spastic Cerebral Palsy1
Not AvailableRecruitingNot AvailableCerebral Palsy (CP)1
Not AvailableRecruitingNot AvailableDetrusor, Overactive / Disseminated Sclerosis / Lower Urinary Tract Symptoms (LUTS) / Neurogenic Bladder Dysfunction / Urge Incontinence1
Not AvailableRecruitingNot AvailableEsthetic Outcome of Injection of Botulinum Toxin Type-A in Cleft Lip Repair1
Not AvailableRecruitingNot AvailableLower Limb Spasticity1
Not AvailableRecruitingNot AvailableMixed Incontinence, Urge and Stress1
Not AvailableRecruitingNot AvailableUrinary Bladder, Overactive1
Not AvailableRecruitingTreatmentChronic Vocal Tic / Gilles de la Tourette's Syndrome1
Not AvailableRecruitingTreatmentEpicondylitis, Lateral Humeral / Lateral Epicondylitis1
Not AvailableRecruitingTreatmentGingival Exposure1
Not AvailableRecruitingTreatmentHemifacial Spasm1
Not AvailableRecruitingTreatmentMigrainous Headache1
Not AvailableRecruitingTreatmentPlantar fascial fibromatosis1
Not AvailableSuspendedTreatmentPain1
Not AvailableTerminatedNot AvailableCerebral Palsy (CP)1
Not AvailableTerminatedTreatmentBrain Injury / Stiff Knee Gait1
Not AvailableTerminatedTreatmentEquinus Contracture1
Not AvailableTerminatedTreatmentErythema and Flushing Associated With Rosacea1
Not AvailableTerminatedTreatmentMigrainous Headache1
Not AvailableTerminatedTreatmentTransient ischemia attacks / Vasopressor1
Not AvailableUnknown StatusTreatmentAlopecia Areata (AA)1
Not AvailableUnknown StatusTreatmentEsophageal Spasm, Diffuse1
Not AvailableUnknown StatusTreatmentFlexion Contracture Following Total Knee Replacement1
Not AvailableUnknown StatusTreatmentLateral Epicondylitis / Type A Botulinum Toxin1
Not AvailableWithdrawnNot AvailableChronic Migraine, Headaches1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Allergan Inc.
  • Tercica Inc.
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntradermal; Intramuscular100 [USP'U]/1
Injection, powder, lyophilized, for solutionIntradermal; Intramuscular200 [USP'U]/1
Powder, for solutionIntramuscular100 unit
Injection, powder, lyophilized, for solutionIntramuscular100 [USP'U]/1
Injection, powder, lyophilized, for solutionIntramuscular50 [USP'U]/1
Injection, powder, lyophilized, for solutionIntramuscular300 U/1
Injection, powder, lyophilized, for solutionIntramuscular300 [USP'U]/1
Injection, powder, lyophilized, for solutionIntramuscular500 U/1
Powder, for solutionIntramuscular300 unit
Powder, for solutionIntramuscular500 unit
Injection, powder, lyophilized, for solutionIntramuscular200 [USP'U]/1
Powder, for solutionIntramuscular50 unit
Prices
Unit descriptionCostUnit
Botox 200 unit vial1260.0USD vial
Dysport 500 unit vial852.0USD vial
Botox 100 unit655.2USD vial
Botox 100 unit vial630.0USD vial
Botox cosmetic 100 unit vial630.0USD vial
Botox cosmetic 50 unit vial346.8USD vial
Botox (100 - 200 unit/Vial)3.74USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2280565No2005-11-152019-08-20Canada
CA2310845No2001-05-152014-06-07Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
hydrophobicity-0.368Not Available
isoelectric point6.06Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Syntaxin-1 binding
Specific Function
t-SNARE involved in the molecular regulation of neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems. Associates with proteins involved in vesi...
Gene Name
SNAP25
Uniprot ID
P60880
Uniprot Name
Synaptosomal-associated protein 25
Molecular Weight
23314.905 Da
References
  1. Zhou JY, Wang ZF, Ren XM, Tang MZ, Shi YL: Antagonism of botulinum toxin type A-induced cleavage of SNAP-25 in rat cerebral synaptosome by toosendanin. FEBS Lett. 2003 Dec 4;555(2):375-9. [PubMed:14644446]
  2. Flynn TC: Myobloc. Dermatol Clin. 2004 Apr;22(2):207-11, vii. [PubMed:15222581]
  3. Okada M, Yoshida S, Zhu G, Kaneko S: [Methodological consideration in studying the exocytosis mechanisms using microdialysis]. Nihon Shinkei Seishin Yakurigaku Zasshi. 2004 Aug;24(4):165-70. [PubMed:15484814]
  4. Frassoni C, Inverardi F, Coco S, Ortino B, Grumelli C, Pozzi D, Verderio C, Matteoli M: Analysis of SNAP-25 immunoreactivity in hippocampal inhibitory neurons during development in culture and in situ. Neuroscience. 2005;131(4):813-23. [PubMed:15749336]
  5. Straughan D: Progress in applying the Three Rs to the potency testing of Botulinum toxin type A. Altern Lab Anim. 2006 Jun;34(3):305-13. [PubMed:16831062]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Gtpase activity
Specific Function
Mediates apoptosis in neoplastically transformed cells after DNA damage. Not essential for development but affects cell adhesion and growth factor signaling in transformed cells. Plays a negative r...
Gene Name
RHOB
Uniprot ID
P62745
Uniprot Name
Rho-related GTP-binding protein RhoB
Molecular Weight
22123.185 Da
References
  1. Ishida H, Zhang X, Erickson K, Ray P: Botulinum toxin type A targets RhoB to inhibit lysophosphatidic acid-stimulated actin reorganization and acetylcholine release in nerve growth factor-treated PC12 cells. J Pharmacol Exp Ther. 2004 Sep;310(3):881-9. Epub 2004 May 12. [PubMed:15140914]

Drug created on June 13, 2005 07:24 / Updated on September 17, 2018 20:35